Drug Trial Radar · NCT02561793
DHEA Versus Placebo in Women With Poor Ovarian Response
Last checked: Nov 20, 2026Latest source record: Jul 6, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
440
Planned (sponsor's estimate)
Start
Oct 2015
Primary completion
Sep 2017
Study completion Sep 2017
Sponsor
- Lead sponsor
- Cairo UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 28, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 20 years, up to 43 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
440 women with expected poor ovarian response undergoing IVF/ICSI (intracytoplasmic sperm injection) will be randomly divided into 2 groups using computer generated random numbers . Group 1 ( study group) will receive Dehydroepiandrosterone (DHEA) 25 mg ( DHEA 25mg, Natrol , USA) t.d.s daily for 12 weeks before starting IVF/ICSI cycle. Group 2 ( control group) will receive a placebo. Patients included in the study will be subjected to full history taking and clinical examination. On the second day of menstruation serum FSH, LH, Prolactin and Oestradiol will be assessed and the antral follicular count (AFC) will be assessed using a vaginal ultrasound scan. AFC will be defined as the number of follicles measuring 3-10mm. All patients will have gonadotropin antagonist protocol with Human menopausal gonadotrophin (HMG) stimulation until the day of (Human chorionic gonadotrophin (HCG) administration. On the day of HCG administration, ovarian ultrasound scan will be performed using a transvaginal probe. Oocytes will be aspirated 34-36 hours after HCG administration. Oocytes will be fertilized and embryos will be transferred. Both groups will be compared regarding the proportion of pregnancy.
Conditions
- Subfertility
Interventions
DHEADrug
Women will receive DHEA 12 weeks before starting IVF/ICSI
PlaceboDrug
women will receive a placebo 12 weeks before starting IVF/ICSI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ongoing pregnancy rateTime frame: 12 weeks after embryo transfer
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Cairo University Hospitals
Cairo, Egypt · Recruiting
Dar AlTeb subfertility centre
Giza, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.